Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
New Jersey: below-average open trial sites
1,145 of 3,402 in-state trials are recruiting (34%); below the 37% national average by 3 percentage points.
According to ClinicalTrials.gov-derived indexes, New Jersey sits in the upper half of US states by in-state trial count (#20 of 52 states by registered in-state trial count).
New Jersey: 3,402 US clinical trials with in-state sites, 1,145 recruiting.
New Jersey has 3,402 registered US clinical trials with a study site in-state, 1,145 of them currently recruiting (below the 37% national average by 3 percentage points). 627 of these trials are in Phase 3 (late-stage) and 917 in Phase 2. The most frequently studied condition in New Jersey is Breast Cancer, with 110 linked trials.
Mid-pack research density
New Jersey sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Below-average open enrollment
New Jersey still shows 1,145 recruiting of 3,402 in-state trials (34% open), but below the 37% national average by 3 percentage points, so archived statuses weigh heavier than the national baseline.
- 34%
- open (below national share)
- 1,145
- still recruiting despite cool share
- 917
- Phase 2 rows in this footprint
- 110
- top: Breast Cancer
Recruiting share is below the 37% national average by 3 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
New Jersey vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
3,402 Top 38% more indexed trials than 62% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for New Jersey on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
New Jersey open-enrollment share sits below the national baseline.
1,145 of 3,402 in-state trials (33.7%) are recruiting, against 37% nationally (-3.3 percentage points). Counts include every study with at least one recorded site in the state.
-
New Jersey trial sites spread across 8 city hubs.
Basking Ridge lists 541 of 3,402 in-state trials (15.9%) across 64 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in New Jersey.
110 of 3,402 in-state trials (3.2%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
One sponsor accounts for a large share of New Jersey trials.
Memorial Sloan Kettering Cancer Center appears on 516 of 3,402 in-state trials (15.2%). Sponsor identity is as filed on ClinicalTrials.gov.
-
1,420 New Jersey trials carry a completed status.
1,420 of 3,402 (41.7%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 1,420 |
| Recruiting | 1,145 |
| Active | 837 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 2 | 917 |
| NA | 671 |
| Phase 1 | 636 |
| Phase 3 | 627 |
| Phase 4 | 125 |
| Early Phase 1 | 25 |
Top Conditions
Top Sponsors
Where trials run in New Jersey
Basking Ridge carries 541 of New Jersey's 3,402 indexed trials (16%) across 64 named sites, ahead of New Brunswick at 501. 8 cities clear five listed trials, together naming 727 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Basking Ridge | 541 | 64 |
| New Brunswick | 501 | 192 |
| Middletown | 490 | 38 |
| Hackensack | 479 | 147 |
| Montvale | 457 | 33 |
| Newark | 207 | 111 |
| Morristown | 185 | 91 |
| Camden | 140 | 51 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Trial size large
New Jersey's in-state trials target 6,445 patients on average (p78 by trial size among 52 states with enrollment data), larger, multi-site studies than most states.
New Jersey: in-state trial volume sits mid-pack
Sites spread across 8 cities with five or more listed trials, led by Basking Ridge (541, 16% of the state total) and New Brunswick (501), together naming 727 distinct research locations.
Phase mix: 627 Phase 3 vs 917 Phase 2 (balanced across stages).
Top condition: Breast Cancer (110 trials); top sponsor Memorial Sloan Kettering Cancer Center (516).
mid-volume · mid-open figures (3,402 trials · 34% open) describe registry geography under the trial size large read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near New Jersey on in-state trial volume
Cross-state peers under the trial size large read (mid-volume · mid-open), not the same-state browse list.
Similar mid-volume peers (± open share)
- Connecticut · 3,531 trials · 32% recruiting
- Indiana · 3,113 trials · 29% recruiting
- Washington · 2,795 trials · 33% recruiting
- Missouri · 4,116 trials · 33% recruiting
- Alabama · 4,168 trials · 29% recruiting